LNP-formulated dbDNA vaccines generated durable functional antibody responses and stronger CD4+/CD8+ T cell immunity than matched mRNA vaccines in non-human primates. These responses were achieved at low dose and accompanied by distinct innate immune activation, supporting dbDNA as a potent synthetic nucleic acid vaccine platform.

À l'origine des premiers vaccins à ARN contre la grippe aviaire, Ceva continue d'innover au service de la santé animale.

The first UK patient has been dosed in the Phase I NEOVACC trial using Touchlight’s proprietary doggybone DNA technology to manufacture a bespoke cancer vaccine.

Touchlight’s dbDNA used in first UK personalised lung cancer vaccine  Manufacturing Chemist

Cell-free dbDNA provides a fast, enzymatic method for producing high-quality DNA without bacterial fermentation. By simplifying workflows and reducing impurities, it shortens development timelines and...

New England Biolabs introduces the EnClose Cell-free dbDNA Synthesis Kit with Touchlight, simplifying DNA therapeutic development and accelerating research.

IPSWICH, Mass., March 18, 2026 /PRNewswire/ -- New England Biolabs (NEB®) today announced the release of the EnClose Cell-free dbDNA Synthesis Kit, developed in collaboration with Touchlight. This novel kit enables the benchtop enzymatic synthesis of Touchlight's proprietary doggybone™...

Touchlight’s dbDNA™ Manufacturing Facility Receives World-First GMP License from MHRA  b3c newswire